Wiley Matthew T. insider trades

Wiley Matthew T. has filed 16 Form 4s with the SEC that we hold, for BioXcel Therapeutics, Inc. (BTAI) (Reporting owner), Definium Therapeutics, Inc. (DFTX) (Chief Commercial Officer) and Yarrow Bioscience, Inc. (VYNE) (Chief Commercial Officer). Across all of them we count 0 purchases worth $0 and 6 sales worth $248.9K reported on Form 4. In the last 12 months: 0 purchases ($0) and 2 sales ($242.4K). The largest single trade was a sale of 2,867 shares of Definium Therapeutics, Inc. worth $129.1K, dated 2026-06-25. Of 1 sale filed since we began reading the 10b5-1 checkbox, 1 (100%) was marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-07-02 and the latest 2026-09-29.

BioXcel Therapeutics, Inc. (BTAI)

Reporting owner · 8 filings · 4 purchases and sales

Trade date	Code	Shares	Value as filed	Filed	Source
2024-04-04	S, sale reported on Form 4	1,008	$2.7K	2024-04-08	SEC
2024-06-17	S, sale reported on Form 4	244	$307	2024-06-18	SEC
2024-09-16	S, sale reported on Form 4	215	$148	2024-09-17	SEC
2024-10-03	S, sale reported on Form 4	6,272	$3.4K	2024-10-03	SEC

Definium Therapeutics, Inc. (DFTX)

Chief Commercial Officer · 7 filings · 2 purchases and sales

Trade date	Code	Shares	Value as filed	Filed	Source
2026-06-25	S, sale reported on Form 4	2,867	$129.1K	2026-06-26	SEC
2026-09-25	S, sale reported on Form 4	3,097	$113.3K	2026-09-29	SEC

Yarrow Bioscience, Inc. (VYNE)

Chief Commercial Officer · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1759703) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-27 · For informational purposes only, not investment advice.
Privacy · Terms